The first report from the patient outcomes registry for transplant effects on life (PORTEL): Differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens

Clinical Transplantation

Volumn 17, Issue 3, 2003, Pages 183-194

  Hathaway, Donna ^a   Winsett, Rebecca ^a   Prendergast, Mary ^b   Subaiya, Indu ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c Quorum Consulting Inc   (United States)

Author keywords

Immunosuppressives; Outcomes; Quality of life; Side effects

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; GINGIVA HYPERTROPHY; GRAFT REJECTION; HAIR DISEASE; HAIR GROWTH; HAND DISEASE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; ORGAN TRANSPLANTATION; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REGISTER; ROLE PLAYING; SCORING SYSTEM; SUPPORT GROUP; TIME; TREMOR; UNITED STATES; UNIVERSITY;

ACTIVITIES OF DAILY LIVING; CYCLOSPORINE; DATA COLLECTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; QUALITY OF LIFE; QUESTIONNAIRES; REGISTRIES; REGRESSION ANALYSIS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0038678033     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2003.00024.x     Document Type: Article

References (25)

1. Laupacis A, Keown P, Pus N et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996: 50: 235.
2. Dew MA, Switzer FE, Goycoolea JM et al. Does transplantation produce quality of life benefits. Transplantation 1997: 64: 1261.
3. Gross CR, Raghu G. The cost of lung transplantation and the quality of life post-transplant. Clin Chest Med 1997: 18: 391.
4. Hathaway DK, Winsett RP, Johnson C et al. Post kidney transplant quality of life prediction models. Clin Transplant 1998: 12: 168.
5. Pinson CW, Feurer ID, Payne JL, Wise PE, Shockley S, Speroff T. Health-related quality of life after different types of solid organ transplantation. Ann Surg 2000: 232: 597.
6. Dew MA. Quality-of-life studies. Organ transplantation research as an exemplar of past progress and future directions. J Psychosom Res 1998: 44: 189.
7. Hathaway D, Strong M, Ganza M. Post-transplant quality of life expectations. ANNA J 1990: 17: 433.
8. Bravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK. Health-related quality of life after liver transplantation: a meta-analysis. Liver Transpl Surg 1999: 5: 318.
9. Rebello P, Ortega F, Baltar JM, Badia X, Alvarez-Ude F et al. Health related quality of life (HRQOL) of kidney transplanted patients: variables that influence it. Clin Transplant 2000: 14: 199.
10. Hathaway DK, Winsett RP, Milstead EJ, Wicks MN, Gaber AO. Quality of life outcomes associated with variable post-transplant prednisone dosing regimens. J Transpl Coord 1996: 6: 64.
11. Aravot D, Berman M, Ben-Gal T, Sahar G, Vidne B. Functional status and quality of life of heart transplant recipients surviving beyond 5 years. Transplantation Proc 2000: 32: 731.
12. Winsett RP, Hathaway DK, Wicks MN, Alloway RR. Design and Development of a Survey Specific for Immunosuppressant Side Effects in Transplant Recipients. Memphis, TN: Proceedings of the Sigma Theta Tau, Beta Theta Chapter-at-Large 2000 Research Conference.
13. De Geest S, Moons P. The patient's appraisal of side-effects: the blind spot in quality-of-life assessments in transplant recipients. Nephrol Dial Transplant 2000: 15: 457.
14. Ellis CN, Reiter KL, Wheeler JRC et al. Economic analysis in dermatology. J Am Acad Dermatol 2002: 46: 271.
15. Rizzo JD, Powe NR. Methodological hurdles in conducting pharmacoeconomic analyses. Pharmacoeconomics 1999: 15: 339.
16. Whiting JF. Standards for economic and quality of life studies in transplantation. Transplantation 2000: 70: 1115.
17. Skinner EA, Steinwachs DM. Patient-reported outcomes of care for schizophrenia and major depression. Abstr Book Assoc Health Serv Res 1998: 15: 51.
18. Woodend AK, Nair RC, Tang AS. Definition of life quality from a patient versus health care professional perspective. Int J Rehabil Res 1997: 20: 71.
19. Ware JE, Snow KK, Kosinski M et al. SF-36 health survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
20. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey. Med Care 1996: 34: 220.
21. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. Comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Fk506 Kidney Transplant Study Group. Transplantation 1997: 63: 977.
22. Shield CF III, McGrath MM, Goss TF. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506) -based versus cyclosporine-based immunosuppression. Fk506 Kidney Transplant Study Group. Transplantation 1997: 64: 1738.
23. Greene WH. Econometric Analysis, 3rd edn. Englewood Cliffs, NJ: Prentice Hall, 1998.
24. Lee SJ, Fairclough D, Parsons SK et al. Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol 2001: 19: 242.
25. Miller RG, Anderson FA, Bradley WG et al. The ALS care database. Neurology 2000: 54.